9:00am - 5:00pm

Office Hours Mon. - Fri.


Call Us For Free Consultation



Phase II Study of Imatinib Mesylate in Patients With Life Threatening Malignant Rare Diseases

Estimated reading time: 1 min


Life Threatening Diseases

Estimated Enrollment: 185

Age Group: 15 Years to 70 Years   (Child, Adult, Senior)

Gender: All

Study Type: Interventional

Study Design Allocation: Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment

Study ID Numbers: CSTI571B2225

Study First Received: September 9, 2005

Last Updated: November 16, 2016

Estimated Primary Completion Date: January 2007

Primary Outcome Measures:

To examine the effect(s) of Imatinib mesylate treatment on life threatening rare diseases with known associations to one or more Imatinib mesylate-sensitive tyrosine kinases|To identify the contribution of specific protein tyrosine kinases (PTKs) of that specific disease|To assess the safety and tolerability of Imatinib mesylate|To evaluate the pharmacokinetic profile of Imatinib mesylate|To assess, where feasible, the functional significance of relevant signal-transduction components in target tissues

Sponsors and Collaborators:

Novartis Pharmaceuticals|Novartis

Result Received: No Study Results Posted

Website Link: https://ClinicalTrials.gov/show/NCT00154388

Was this article helpful?
Views: 76